Financial Insights Inc. Has $499,000 Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

of the company’s stock after buying an additional 2,074 shares during the quarter. Financial Insights Inc. increased its stake in BioMarin Pharmaceutical Inc. by 75.6% in the fourth quarter. The firm now owns 4,823 shares of the company's stock.

After purchasing 2,076 additional shares, the firm now owns 4,823 shares. Financial Insights Inc. held BioMarin Pharmaceutical stock worth $499,000.

BMRN shares have been bought and sold by a number of institutional investors. Arlington Capital Management Inc. purchased a new stake of BioMarin pharmaceutical shares in the fourth quarter, worth approximately $1,150,000. Abrdn plc increased its holdings of BioMarin pharmaceutical by 6.8% in the fourth quarter. Abrdn Plc owns 17,629 of the biotechnology firm's shares worth $1,824,000. It acquired an additional 1,122 during the period. Qsemble Capital Management LP purchased a new stake of BioMarin pharmaceutical shares worth $838,000. Bank of Nova Scotia increased its holdings of BioMarin Pharma by 4,981.1% in the fourth quarter. Bank of Nova Scotia owns 216 049 shares of BioMarin Pharmaceutical stock, worth $22,359,000, after purchasing an additional 211 797 shares. Great Lakes Advisors LLC also acquired shares of BioMarin Pharma during the fourth quarter, worth $249,000. BMRN was the subject of many research reports. Guggenheim reduced their target price for BioMarin Pharmaceutical on Thursday, April 27, from $125.00 down to $120.00. In a research report published on Thursday, BioMarin Pharmaceutical shares were covered. They gave the company a rating of 'buy.' Sanford C. Bernstein began covering BioMarin Pharmaceutical shares in a research report on Tuesday, 21st March. The company was given an 'underperform rating' and a price target of $81.00. SVB Leerink raised their price target on BioMarin Pharmaceutical shares from $120.00 to $130.00 in a research report on Friday, Feb. 3rd. They also gave the stock an "outperform" rating. Seven analysts have given the stock a hold recommendation, while twelve others have recommended that the company be bought. According to MarketBeat data, BioMarin Pharmaceutical has a current consensus rating of "Moderate buy" and an average price target of $118.65.

Insiders Bet on the Future

On Monday, 13th March, 8,000 shares were sold. Stock was sold for $723,600.00 at an average price $90.45. The chief executive now owns directly 487,856 company shares, worth $44,126.575.20. In a deal dated March 13th, 8,000 BioMarin Pharmaceutical shares were sold. Stock was sold for $723,600.00 at an average of $90.45. After the completion of this transaction, the CEO now owns directly 487,856 of the company's shares, valued at $44,126.575.20. In a deal dated April 3, 2008, the company sold 8,500 shares. The shares were purchased at an average of $97.09 for a value of $825.265.00. After the sale, the director owns 28,950 company shares, worth approximately $2,810 755.50. Insiders sold 81.500 shares of stock worth $7.735,465. Insiders own 1.84%.

BioMarin Pharmaceuticals Trading down 0.4 %

The stock fell $0.33 in the trading hours of Friday to $91.90. The trading volume was 766,254 compared to the average of 1,105762. The market cap is $17.25 billion. It has a P/E ratio of 241.84 with a beta value of 0.38. The company's quick ratio is 3.21, its current ratio is 4.75 and its debt-to equity ratio is 0.23. The company's simple moving 50-day average is $94,77, and its simple 200-day average is $99,76. BioMarin Pharma Inc.'s one-year low is $70.73 while its one-year high is $117.77.

The last time the company released its results was on February 27th. The biotechnology firm reported $0.11 per share for the quarter. This was below the consensus estimate ($0.01) of $0.12. BioMarin Pharmaceutical reported a return of equity of 4.02%, and a margin net of 3.30%. Revenue for the quarter was $537.54m, which is higher than analyst expectations of $533.88m. Analysts predict on average that BioMarin Pharma Inc. will earn 1.06 EPS in the current fiscal period.

BioMarin Pharmaceutical Company profile

Get Rating

BioMarin Pharmaceutical, Inc is a company that develops and markets therapies for serious and life-threatening medical conditions and rare diseases. The company's pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 John C. Klock and Christopher M.

Get Rating
). offers a FREE daily email newsletter